Clinical response to azacitidine in MDS is associated with distinct DNA methylation changes in HSPCs.
Thoms JAI, Yan F, Hampton HR, Davidson S, Joshi S, Saw J, Sarowar CH, Lim XY, Nunez AC, Kakadia PM, Bhuyan GS, Zou X, Nguyen M, Ghodousi ES, Koch FC, Vafaee F, Thompson IR, Karimi MM, Pickford R, Raftery MJ, Hough S, Buckland G, Bailey M, Ghodke Y, Absar N, Vaughan L, Pasalic L, Fong CY, Kenealy M, Hiwase DK, Stoddart RI, Mohammed S, Lee L, Passam FH, Larsen SR, Spring KJ, Skarratt KK, Rebeiro P, Presgrave P, Stevenson WS, Ling S, Tiley C, Fuller SJ, Roncolato F, Enjeti AK, Hoenemann D, Lemech C, Jolly CJ, Bohlander SK, Curtis DJ, Wong JWH, Unnikrishnan A, Hertzberg M, Olivier J, Polizzotto MN, Pimanda JE.
Thoms JAI, et al.
Nat Commun. 2025 May 13;16(1):4451. doi: 10.1038/s41467-025-59796-x.
Nat Commun. 2025.
PMID: 40360497
Free PMC article.
Clinical Trial.